ESOPHAGUS CANCER

This study tests a new way to give chemotherapy for gastrointestinal cancers like colorectal and stomach cancer. Doctors will adjust the dose of one chemo drug (5-FU) based on how well each patient tolerates it, aiming to give higher doses to those who can handle it without sever…

This phase II trial is testing a combination of proton radiation and chemotherapy (carboplatin and paclitaxel) before surgery for patients with resectable esophageal or esophagogastric junction cancer. The goal is to see if this approach is safe, tolerable, and effective at impro…

This early-phase trial is testing a new targeted drug called CA-4948 combined with standard chemotherapy and immunotherapy for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. The study will enroll 42 participants an…

This study tests a new drug called ivonescimab combined with standard chemotherapy (FOLFOX) in people with advanced HER2-negative stomach or esophagus cancer that has not been treated before. The goal is to see if the combination can keep the cancer from growing for at least 6 mo…

This study is looking at the best way to treat esophageal cancer that cannot be removed by surgery. It will follow 2,000 patients who receive chemoradiotherapy (radiation plus chemotherapy) along with possible immunotherapy or targeted drugs. The goal is to see which combinations…

This study tests a combination of two drugs, afatinib and palbociclib, in people with advanced esophageal cancer that has come back or spread after prior treatment. The goal is to find a safe dose and see if the combo can shrink tumors. About 45 adults aged 18 to 75 with a specif…

This study is testing a new type of PET scan that uses special probes to highlight digestive system cancers, such as stomach, liver, colon, and pancreatic cancers. Researchers will enroll 400 adults to see how well this imaging method finds tumors and tracks their response to tre…

This study tests whether a combination of two drugs, fosrolapitant and palonosetron, plus a steroid, can prevent nausea and vomiting caused by chemotherapy and immunotherapy in people with esophageal or lung cancer. About 120 participants will receive the drug before each chemo c…

This study tests whether using virtual reality (VR) can reduce severe belly pain and improve quality of life in people with digestive tract cancers. 360 participants will be split into three groups: one using a skills-based VR program, one using distracting VR videos, and a contr…

This study uses artificial intelligence to analyze patient data—like medical history, scans, and lab results—to predict how well esophageal cancer patients respond to chemoimmunotherapy before surgery. Researchers aim to build a model that identifies who achieves a complete respo…

This study is collecting survey responses from 1,000 people who have had or will have surgery on their esophagus. The goal is to validate new questionnaires that measure recovery and symptoms. The information will help doctors set expected recovery scores and improve treatment pl…

This study reviews the medical records of about 4000 people who had surgery for esophageal cancer. The goal is to see how the amount of cancer left at the edges of the removed tissue affects how long people live. No new treatments are given; the study only looks at past informati…

This study is a large registry that will follow about 8,000 cancer patients who receive radiation therapy using a special machine called an MR-Linac, which combines an MRI scanner with a radiation beam. The goal is to learn how well this technology works for different cancers, in…